Stocks making the biggest moves premarket: U.S. Steel, Roku and more


AI Summary Hide AI Generated Summary

Summary of Premarket Stock Movements

This article reports on the significant premarket stock movements of several companies. Key highlights include:

  • U.S. Steel: Shares jumped 5% following President Trump's approval of its merger with Nippon Steel and a national security agreement.
  • Roku: Experienced an 8.5% increase after announcing an exclusive partnership with Amazon, expanding its reach to 80 million U.S. households.
  • Advanced Micro Devices (AMD): Gained over 2% due to a price target increase from Piper Sandler, driven by expectations of growth in its AI business.
  • EchoStar: Saw a dramatic 40%+ surge following reports of President Trump's intervention in a spectrum dispute.
  • Celsius: Rallied 4% after TD Cowen upgraded its stock, citing positive growth prospects.
  • Victoria's Secret: Increased by 3% after activist investor Barington Capital Group disclosed a stake and plans for board changes.
  • Sage Therapeutics: Soared 35% upon agreeing to an acquisition by Supernus Pharmaceuticals.
  • Sarepta Therapeutics: Plunged over 37% after reporting the death of a second patient receiving its Elevidys gene therapy.

The report concludes with acknowledgement of contributions from CNBC's Jesse Pound and Michelle Fox.

Sign in to unlock more AI features Sign in with Google

Check out the companies making headlines before the opening bell on Wall Street: U.S. Steel — U.S. Steel shares jumped 5% after President Donald Trump issued an executive order on Friday approving its merger with Japan's Nippon Steel. The companies also signed a national security agreement that includes a golden share for the U.S government. Although U.S. Steel did not specify what powers the government would wield with its share, Trump said on Thursday that the golden share gives the U.S. president " total control ." Roku — The streaming platform jumped 8.5% after announcing an exclusive partnership with Amazon that gives advertisers access to what the two called "the largest authenticated footprint in connected TV ." The agreement enables advertisers to reach roughly 80 million U.S. households through the Amazon platform. Advanced Micro Devices — The chipmaker added more than 2% after a price target increase from Piper Sandler. After AMD's quarterly pre-quarter close call on Friday, Piper said it expects AMD's artificial intelligence business to surge after the third quarter when China-related charges have passed, and noted increased conviction among investors about a key hyperscaler client. EchoStar — The satellite company jumped more than 40% after Bloomberg News reported late Friday that President Donald Trump had pushed the head of the Federal Communications Commission to resolve a spectrum dispute. The company has threatened to file for bankruptcy protection and claims FCC threats blocked its ability to decide on a 5G network buildout. Celsius — Shares of the energy drink company rallied about 4% after TD Cowen upgraded the stock to buy from hold , saying its "growth story is heating back up" and shares should trade higher this year. The investment bank said it is confident in the Celsius brand, the smooth integration of the company's Alani Nu acquisition and wider distribution next year. Victoria's Secret — Shares added 3% following a report that activist investor Barington Capital Group has built a stake in the retailer. Barington intends to push Victoria's Secret to overhaul its board and refocus its business, The Wall Street Journal said, citing unnamed sources. Sage Therapeutics — Sage soared 35% after agreeing to be acquired by Supernus Pharmaceuticals in a deal worth $12 a share, or $795 million. The deal would diversify Supernus' revenue base and add FDA-approved postpartum depression drug treatment Zurzuvae, according to a statement. Sage shareholders would receive $8.50 a share in cash and a non-tradable contingent value right payable upon certain specific milestones worth up to $3.50 per share. Sarepta Therapeutics — The biopharmaceutical company plunged more than 37% after Sarepta reported the death of a second patient receiving its Elevidys gene therapy for Duchenne muscular dystrophy. Sarepta halted shipments of Elevidys and is taking steps to improve safety for non-ambulatory patients. — CNBC's Jesse Pound and Michelle Fox contributed reporting.

Was this article displayed correctly? Not happy with what you see?

We located an Open Access version of this article, legally shared by the author or publisher. Open It
Tabs Reminder: Tabs piling up in your browser? Set a reminder for them, close them and get notified at the right time.

Try our Chrome extension today!


Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more

Facebook

Save articles to reading lists
and access them on any device


Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more

Facebook

Save articles to reading lists
and access them on any device